L-Glutamine in sickle cell disease.

Area of Science:

• Biochemistry
• Hematology
• Metabolic Medicine

Background:

• L-Glutamine is crucial for nucleotide synthesis and cellular redox balance.
• Sickle cell disease (SCD) is characterized by oxidative stress, impacting red blood cells (RBCs).
• The redox ratio in SCD RBCs is lower, highlighting the importance of glutamine.

Purpose of the Study:

• To evaluate the safety and efficacy of L-Glutamine in treating sickle cell disease.
• To assess the impact of L-Glutamine on clinical outcomes in SCD patients.

Main Methods:

• Phase II and III randomized, double-blind, placebo-controlled trials.
• Participants included children and adults with SCD experiencing at least two pain episodes annually.
• L-Glutamine dosage was 0.6 g/kg/day compared to placebo.

Main Results:

• L-Glutamine is safe for SCD patients and reduces painful episodes and hospitalizations.
• Oral L-Glutamine increased NADH levels and reduced RBC adhesion in prior small studies.
• L-Glutamine was tolerated by two-thirds of patients; anemia and hemolysis did not improve.

Conclusions:

• L-Glutamine demonstrates safety and efficacy in reducing SCD complications.
• Further research is needed on optimal dosing, tolerance, and the role of other nutrients.
• Investigating other amino acids and total protein intake is recommended for future studies.